N |
3130 |
1823 |
1307 |
|
Age of onset (years): mean±SD |
34.7±12.5 |
33.5±12.0 |
36.2±13.0 |
<0.001 |
Personality disorders: n (%) |
181 (5.8) |
148 (8.1) |
32 (2.4) |
<0.001 |
Pervasive developmental disorders: n (%) |
207 (6.6) |
148 (8.1) |
59 (4.5) |
<0.001 |
Alcohol/substance abuse: n (%) |
167 (5.3) |
133 (7.3) |
34 (2.6) |
<0.001 |
Physical comorbidity: n (%) |
968 (30.9) |
557 (30.6) |
411 (31.4) |
0.601 |
Rapid cycling: n (%) |
329 (10.5) |
264 (14.5) |
65 (5.0) |
<0.001 |
Social function: n (%) |
|
|
|
<0.001 |
Global Assessment of Functioning 81–100 |
1008 (32.2) |
203 (11.1) |
805 (61.6) |
|
Global Assessment of Functioning 61–80 |
1407 (45.0) |
972 (53.3) |
435 (33.3) |
|
Global Assessment of Functioning 41–60 |
606 (19.4) |
550 (30.2) |
56 (4.3) |
|
Global Assessment of Functioning 1–40 |
87 (2.8) |
81 (4.4) |
6 (0.5) |
|
Pharmacological treatment: n (%) |
3104 (99.2) |
1811 (99.3) |
1293 (98.9) |
0.147 |
Mood stabilizers: n (%) |
|
|
|
|
Lithium |
1488 (47.5) |
783 (43.0) |
705 (53.9) |
<0.001 |
Valproic acid |
893 (28.5) |
533 (29.2) |
358 (27.4) |
0.259 |
Carbamazepine |
149 (4.8) |
97 (5.3) |
52 (4.0) |
0.082 |
Lamotrigine |
744 (23.8) |
481 (26.4) |
263 (20.1) |
<0.001 |
Antipsychotics: n (%) |
1692 (54.1) |
1081 (59.3) |
611 (46.7) |
<0.001 |
Antidepressants: n (%) |
1291 (41.2) |
828 (45.4) |
463 (35.4) |
<0.001 |
Anxiolytics: n (%) |
1133 (36.2) |
739 (40.6) |
394 (30.2) |
<0.001 |
Hypnotics: n (%) |
1886 (60.3) |
1213 (66.5) |
673 (51.5) |
<0.001 |